Entero Therapeutics (ENTO) Insider Trading & Ownership $0.49 -0.03 (-4.82%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.50 +0.00 (+0.55%) As of 02/21/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Insider Trades Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends Entero Therapeutics (NASDAQ:ENTO) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage0.49%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)2Amount OfInsider Selling(Last 12 Months)$2,723.18 Get ENTO Insider Trade Alerts Want to know when executives and insiders are buying or selling Entero Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address ENTO Insider Buying and Selling by Quarter Entero Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails1/6/2025Sarah RomanoCFOSell727$0.64$465.28 10/9/2024Sarah RomanoCFOSell476$0.45$214.20 7/2/2024James SapirsteinCEOSell1,289$1.07$1,379.23 7/2/2024Sarah RomanoCFOSell621$1.07$664.47 (Data available from 1/1/2013 forward) ENTO Insider Trading Activity - Frequently Asked Questions Who is on Entero Therapeutics's Insider Roster? The list of insiders at Entero Therapeutics includes James Sapirstein, and Sarah Romano. Learn more on insiders at ENTO. What percentage of Entero Therapeutics stock is owned by insiders? 0.49% of Entero Therapeutics stock is owned by insiders. Learn more on ENTO's insider holdings. Which Entero Therapeutics insiders have been selling company stock? The following insiders have sold ENTO shares in the last 24 months: James Sapirstein ($1,379.23), and Sarah Romano ($1,343.95). How much insider selling is happening at Entero Therapeutics? Insiders have sold a total of 3,113 Entero Therapeutics shares in the last 24 months for a total of $2,723.18 sold. Entero Therapeutics Key ExecutivesMr. James R. Sapirstein M.B.A. (Age 63)R.Ph., CEO & Chairman Compensation: $906.2kDr. Jack A. Syage Ph.D. (Age 69)President, COO & Director Ms. Amy Chandler-Skerkis (Age 56)Vice President of Regulatory Affairs, QA & Compliance Mr. Martin Krusin M.B.A.Senior Vice President of Corporate Development More Insider Trading Tools from MarketBeat Related Companies AYTU Insider Ownership AIM Insider Ownership CELZ Insider Ownership CYCN Insider Ownership EDSA Insider Ownership INDP Insider Ownership ENSC Insider Ownership CNSP Insider Ownership EVOK Insider Ownership HOTH Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Stocks With Robust Growth Outlooks Insiders Are BuyingMETA Stock: Insider Selling Ramps Up—What It Means for InvestorsThese Are the Dividend Stocks Insiders Bought in JanuaryInsider Selling in Tech Stocks Spikes in Q43 Small-Cap Stocks Insiders and Institutions Are Buying This page (NASDAQ:ENTO) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredHow to trade Executive Order 14154Trump’s pen must be running out of ink… Since he returned to office he’s signed more than 50 Executive Orde...Porter & Company | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
